{"organizations": ["Merus BV"], "uuid": "9a7764d13bea190eb5dcb0b325912de478b15156", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530658?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Merus BV closes first tranche of €72.8mm Series C round", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Merus BV closes first tranche of €72.8mm Series C round", "spam_score": 0.0, "site_type": "news", "published": "2015-08-29T02:40:00.000+03:00", "replies_count": 0, "uuid": "9a7764d13bea190eb5dcb0b325912de478b15156"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530658?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Merus BV closes first tranche of €72.8mm Series C round", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Merus BV closes first tranche of €72.8mm Series C round Deal Date: Aug-01-2015 / Deal # 201530658 Executive Summary \nMerus BV (immuno-oncology therapies) closed the first tranche of its €72.8mm ($82.2mm) Series C round. New investors Sofinnova Ventures and Novo AS co-led and take board seats, and were joined by other first-time buyers RA Capital Healthcare Fund, Rock Springs Capital, Tekla Capital Management, and an unnamed US-based investor, along with returning backers Novartis Venture Fund, Johnson & Johnson Innovation (JJDC), Pfizer Venture Investments, Bay City Capital, LSP Life Sciences Partners, and Aglaia Oncology Fund.", "external_links": [], "published": "2015-08-29T02:40:00.000+03:00", "crawled": "2015-08-29T18:11:35.999+03:00", "highlightTitle": ""}